BlueWillow Biologics is developing #intranasal #vaccines that enable #mucosalimmunity, the body's first line of defense, while also inducing systemic immunity. bit.ly/2Q7S4Ro

Check out this opinion piece from Scientific American that discusses the potential advantages of stopping the spread of #COVID19 using #nasal #vaccines. bit.ly/320cgqA

On Good Morning America, Dr Jennifer Ashton sheds light on the potential benefits of #COVID19 #intranasal #vaccines. "There is a #mucosalimmunity that can be generated via a nasal spray vaccination method that also has the potential for reducing transmission." gma.abc/3uAsh2V"

A review published in Taylor & Francis Research Insights's Human Vaccines & Immunotherapeutics explores approaches to an effective #mucosal #vaccine formulation, which can potentially induce long-lasting systemic and #mucosalimmunity to confer protection against #COVID19. bit.ly/3d2C3Fe

Working with Medigen, we continue our mission to develop a nasal #vaccine for SARS-CoV-2, the virus that causes #COVID19. bit.ly/3mJwz5a

This Quartz article discusses how inhaled nasal vaccines can become the future of inoculation due to potential ease of access and use as well as increased effectiveness. bit.ly/39XJyuU

BlueWillow Biologics's #intranasal #COVID19 vaccine may generate #mucosalimmunity and block transmission at the site of infection. bit.ly/3g63kXA MedPage Today explores the potential advantages of a #nasal #vaccine compared to intramuscular vaccines. bit.ly/3pc2gWb

A Healthline article discusses how an #intranasal #COVID19 #vaccine could make the global vaccination process both simpler and faster. bit.ly/3yO0KOt BlueWillow Biologics is working with Medigen to develop S-2P-NE-01, a nasal #vaccine for SARS-CoV-2. bit.ly/3igwBkW

BlueWillow Biologics's #intranasal #COVID19 vaccine may strengthen the body's immune response by inducing #mucosalimmunity. bit.ly/3g63kXA This review discusses how #nasal #vaccines can potentially serve as a booster for intramuscular vaccines. bit.ly/3fLbIwN

BlueWillow Biologics announces positive interim results from the Phase 1 trial of its intranasal anthrax vaccine. bwnews.pr/3mtRbR8

Interesting SportsTravelAndTours Pharmalot article on how the Omicron variant has emphasized the need for vaccine equity across our global community. bit.ly/3IbF1Vd

We agree w Ashish K. Jha – as the need for global vaccinations grows, we must turn to next gen non-needle options as a potential solution. #intranasal vaccines can induce mucosal immunity & are easier-to-administer, more patient-friendly & straightforward to manufacture & transport

As #COVID19 variants continue to emerge, there is an impending need for a solution that inhibits nasal carriage of the virus and prevents transmission. Working with Medigen, BlueWillow continues our mission to develop an #intranasal #booster #vaccine. bit.ly/3If5t0q

Our President and CEO, Chad Costley, MD, shared insights regarding the benefits of #intranasal vaccines with BioSpace. Check out how BlueWillow is developing the next generation of safe and effective vaccines: bit.ly/3r5vAjG

BlueWillow Biologics is developing #intranasal #vaccines that enable #mucosalimmunity, the body's first line of defense, while simultaneously inducing systemic immunity. bit.ly/2Q7S4Ro

Important article in The New York Times about the benefits of #intranasalvaccines over injections for #COVID19, but virus-based delivery is not the only solution. BlueWillow has an #intranasal adjuvant that has been proven to be safe in humans. Learn more at bluewillow.com

“Intranasal vaccination has now reached the precipice of transforming the vaccine industry -- the long sought-after promise of protective, needle-free and inexpensive vaccination is now within our reach.” Read more on Scrip, Citeline Commercial: bit.ly/3oRp3aM

In collaboration with Medigen, BlueWillow Biologics announces positive results for #intranasal #COVID19 #booster candidate in pre-clinical studies. Learn more: bwnews.pr/3hwZ3xp

BlueWillow’s novel adjuvant platform has broad implications in developing nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Read about our peanut allergy program in SnackSafely.com: bit.ly/3oVe5ks

Our President & CEO, Chad Costley, MD, shared insights regarding the historical development of #mucosal, specifically #intranasal vaccines, their advantages over intramuscular ones, and what the future holds for BlueWillow with Pharma's Almanac. Learn more: bit.ly/3KpDsTD